Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

485
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
485
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

388
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
388
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

229
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
229
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A non-hydrolyzable candesartan cilexetil analog reveals synergistic activation as a tractable mechanism for TMEM175 modulation.

American journal of physiology. Cell physiology·2026
Same author

Discovery of Kv3.1 channel inhibitors reveals VU0521426 as a state-dependent inactivator preferentially active against pathogenic gain-of-function mutants.

American journal of physiology. Cell physiology·2026
Same author

Activation of TMEM175 lysosomal ion channels by CysLT1 receptor antagonists.

American journal of physiology. Cell physiology·2026
Same author

A conserved mechanism of LRRC8 channel inhibition by two structurally distinct drugs.

Communications biology·2025
Same author

Automated patch clamp analysis of heterologously expressed Kir6.2/SUR1 and Kir6.1/SUR2B K<sub>ATP</sub> currents.

American journal of physiology. Cell physiology·2025
Same author

K<sub>ir</sub>7.1 knockdown and inhibition alter renal electrolyte handling but not the development of hypertension in Dahl salt-sensitive rats.

American journal of physiology. Renal physiology·2023
Same journal

Cryo-EM sheds light on the mechanism of human telomerase inhibition by BIBR1532.

Nature chemical biology·2026
Same journal

Artificial metalloenzymes in complex biological environments.

Nature chemical biology·2026
Same journal

Allosteric disordering of eIF2B regulates the integrated stress response.

Nature chemical biology·2026
Same journal

A tail of two ligases.

Nature chemical biology·2026
Same journal

Non-canonical cytochrome P450 enzymes expand the diversity of bacterial hemoproteins.

Nature chemical biology·2026
Same journal

Image-guided activation of drugs with electromagnetic radiation.

Nature chemical biology·2026
See all related articles

Related Experiment Video

Updated: Jul 1, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

50

Dam antidepressants

Jerod S Denton1,2

  • 1Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA. jerod.s.denton@vumc.org.

Nature Chemical Biology
|March 7, 2024
PubMed
Summary

No abstract available in PubMed .

More Related Videos

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

37.3K
Using Chronic Social Stress to Model Postpartum Depression in Lactating Rodents
07:30

Using Chronic Social Stress to Model Postpartum Depression in Lactating Rodents

Published on: June 10, 2013

24.8K

Related Experiment Videos

Last Updated: Jul 1, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

50
The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

37.3K
Using Chronic Social Stress to Model Postpartum Depression in Lactating Rodents
07:30

Using Chronic Social Stress to Model Postpartum Depression in Lactating Rodents

Published on: June 10, 2013

24.8K